A descriptive case series: Oral transmucosal fentanyl use in patients with noncancerous pain

Anthony H. Guarino, MD; Jennifer Myers, RN, MSN, ANP; Martha E. Cornell, RN, BSN

doi:10.5055/jom.2006.0013

Authors

Anthony H. Guarino, MD
Jennifer Myers, RN, MSN, ANP
Martha E. Cornell, RN, BSN

DOI:

https://doi.org/10.5055/jom.2006.0013

Keywords:

Transmucosal fentanyl, Actiq, noncancerous pain, breakthrough pain, opioid

Abstract

Transmucosal fentanyl is indicated for patients with cancer who are opioid tolerant, but it is also used for the treatment of noncancerous pain. The following is a survey study of the use of transmucosal fentanyl in 29 patients with noncancerous pain in an academic, communitybased pain management practice. Trans mucosal fentanyl was found to be safe and efficacious in the patients studied.

Author Biographies

Anthony H. Guarino, MD

Washington University in St. Louis, Department of Anesthesiology, St. Louis, Missouri.

Jennifer Myers, RN, MSN, ANP

Washington University in St. Louis, Department of Anesthesiology, St. Louis, Missouri.

Martha E. Cornell, RN, BSN

Washington University in St. Louis, Department of Anesthesiology, St. Louis, Missouri.

References

Actiq (oral transmucosal fentanyl citrate) [package insert]. Salt Lake City: Cephalon, Inc. 2004.

Rhiner M, Kedziera P: Managing breakthrough cancer pain: A new approach. Home Healthc Nurse. 1999;17 (suppl.): 1-12; quiz 13-15.

Rees E: The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain. Int J Palliat Nurs. 2002; 8: 304-308.

Portenoy RK, Payne R, Coluzzi P, et al.: Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: A controlled dose titration study. Pain. 1999; 79: 303-312.

Payne R, Coluzzi P, Hart L, et al.: Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage. 2001; 22: 575-583.

Mercadante S, Fulfaro F: Alternatives to oral opioids for cancer pain. Oncology (Huntingt). 1999; 13: 215-220, 225; discussion 226-229.

Coluzzi PH, Schwartzberg L, Conroy JD, et al.: Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001; 91: 123-130.

Oral transmucosal fentanyl for breakthrough cancer pain when morphine fails. Prescrire Int. 2002; 11: 106-107.

Farrar JT, Portenoy RK, Berlin JA, et al.: Defining the clinically important difference in pain outcome measures. Pain. 2000; 88: 287-294.

Streisand JB, Busch MA, Egan TD, et al.: Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology. 1998; 88: 305-309.

Egan TD, Sharma A, Ashburn MA, et al.: Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology. 2000; 92: 665-673.

Zeppetella G, O’Doherty CA, Collins S: Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000; 20: 87-92.

Portenoy RK, Hagen NA: Breakthrough pain: Definition, prevalence and characteristics. Pain 1990; 41: 273-281.

Fine PG, Busch MA: Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage. 1998; 16: 179-183.

Caraceni A, Portenoy RK: An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain. 1999; 82: 263-274.

Ingham J, Seidman A, Yao TJ, et al.: An exploratory study of frequent pain measurement in a cancer clinical trial. Qual Life Res. 1996; 5: 503-507.

Jacox A, Carr DB, Payne R: New clinical-practice guidelines for the management of pain in patients with cancer. N Engl J Med. 1994; 330: 651-655.